Harmony Biosciences Holdings, I — Earnings Quality Grade A
HRMY · Healthcare
Strong financial health
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 41 days, change -2 days YoY
AR growth 16.6% vs revenue growth 21.5%
Revenue 21.5%, CFFO 58.4%. Cash follows revenue
Expense Quality
Inventory -25.6% vs COGS 26.5%. Normal
CapEx growth -73.1% vs revenue 21.5%. Normal
SG&A/Gross Profit = 40.6%. Normal
Gross margin 77.2%, change -0.9pp. Stable
Cash Flow Quality
CFFO/NI = 2.19. Profits backed by cash
FCF $0.3B, FCF/NI = 2.19
Accruals ratio = -14.9%. Low accruals
Cash $0.8B covers debt $0.2B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = 0.6x. Healthy
Other assets grew 147.8% vs revenue 21.5%
No write-off data
Acquisition Risk
FCF after acquisitions positive
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor HRMY continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25